What THERMO FISHER SCIENTIFIC INC.'s SEC filings said

10-Q for 2026Q3, filed 30 Oct 2026, and 1 8-K since. Each line is something a filing stated, ranked by score and linked to its source.

Ranked highest

Acquisitions and Divestitures81 · importance in its document · 8-K exhibit · 21 Oct 2026
Thermo Fisher completed the previously announced divestiture of its microbiology business during the third quarter of 2026. Nine-month cash proceeds from the sale of a business, net of cash divested, were $1.021 billion. The company…
Income Tax Rate Changes59 · importance in its document · 10-Q · 2026Q3
The third-quarter 2026 GAAP tax rate was 16.9%, compared with 11.3% a year earlier, and the adjusted rate was 11.6%, compared with 11.0%. A $161 million deferred tax benefit from recognized tax attributes related to a domestication…
Free Cash Flow56 · importance in its document · 8-K exhibit · 21 Oct 2026
Nine-month free cash flow increased 39% to $4.618 billion from $3.319 billion in 2025. Net cash provided by operating activities rose to $5.867 billion from $4.361 billion. Purchases of property, plant and equipment totaled $1.263…
Guidance / Outlook54 · importance in its document · 10-Q · 2026Q3
Thermo Fisher expects 2026 GAAP effective tax rates of 9% to 11% and an adjusted tax rate of approximately 11.5%. The forecast reflects currently expected profitability across the countries where the company operates and generates foreign…

Ranked by score, 0–100. A topic read from a document carries its importance within that document; an 8-K event carries the rule score that ranks a filing among filings. Neither is about the share price, and the two scales are named on each row because they are not the same measure.

Latest report: 10-Q · 2026Q3 filed 30 Oct 2026

Full report · Filing on EDGAR

Acquisitions and DivestituresImportance 65
On March 24, 2026, Thermo Fisher acquired Clario Holdings, a U.S. clinical-trial endpoint data provider, for its Laboratory Products and Biopharma Services segment. The acquisition contributed to $425 million of…
Income Tax Rate ChangesImportance 59
The third-quarter 2026 GAAP tax rate was 16.9%, compared with 11.3% a year earlier, and the adjusted rate was 11.6%, compared with 11.0%. A $161 million deferred tax benefit from recognized tax attributes related to a…
Guidance / OutlookImportance 54
Thermo Fisher expects 2026 GAAP effective tax rates of 9% to 11% and an adjusted tax rate of approximately 11.5%. The forecast reflects currently expected profitability across the countries where the company operates…
Operating Cash Flow TrendsImportance 52
Net cash provided by operating activities increased to $5.867 billion in the first nine months of 2026 from $4.361 billion in the comparable 2025 period. Free cash flow rose to $4.618 billion from $3.319 billion, while…
Share Repurchase ProgramImportance 52
The company repurchased $4.00 billion of common stock, or 6.9 million shares, in the first nine months of 2026, compared with $3.00 billion, or 5.8 million shares, in the prior-year period. All 2026 repurchases were…
Capital ExpendituresImportance 52
Thermo Fisher spent $1.26 billion on property, plant and equipment for capacity and capability investments in the first nine months of 2026, compared with $1.06 billion in the prior-year period. The company expected…
Capital Expenditure OutlookImportance 42
For all of 2026, Thermo Fisher expects property, plant and equipment expenditures, net of disposals, to be between $1.9 billion and $2.0 billion. The company says these investments support capacity and capability.…
Liquidity and Debt PositionImportance 42
At September 26, 2026, Thermo Fisher held $5.461 billion of cash and cash equivalents, down from $9.852 billion at December 31, 2025, and reported total debt of $41.370 billion, up from $39.384 billion. Short-term…
Revenue Performance and MixImportance 36
Third-quarter 2026 revenue was $12.137 billion, up 9.1% from $11.122 billion a year earlier; revenue for the first nine months was $35.136 billion, up 8.6% from $32.341 billion. Third-quarter segment revenue was $6.863…
Instrument and Bioproduction DemandImportance 32 · +2 more on this subject
Life Sciences Solutions’ organic revenue growth in the third quarter and first nine months of 2026 was driven by bioproduction, with higher demand from pharma and biotech customers. Analytical Instruments’ organic…
Gross Margin DriversImportance 31
Consolidated GAAP operating margin increased to 18.6% in the third quarter of 2026 from 17.4% in the prior-year quarter and to 17.7% for the first nine months from 17.0%. Adjusted operating margin rose to 24.5% in the…
Geographic Market CommentaryImportance 26
In the third quarter of 2026, sales increased across all major geographies. Growth was strong in North America and Europe and very strong in Asia-Pacific, including China. For the first nine months, sales grew in North…

8-K filings last 12 months

Other officer change30 Oct 2026 · 8-K Item 5.02 · Routine · rule score 15
“On October 27, 2026, Thermo Fisher Scientific Inc. (the “Company”), announced that Michael D. Shafer, Executive Vice President of the Company, will retire effective December 31, 2026. 2”
Results (release not read)21 Oct 2026 · 8-K Item 2.02 · Routine · rule score 20
Read from the attached exhibit: Acquisitions and Divestitures · Free Cash Flow · Revenue Performance and Mix
Results (release not read)23 Jul 2026 · 8-K Item 2.02 · Routine · rule score 20
Results (release not read)23 Apr 2026 · 8-K Item 2.02 · Routine · rule score 20
Results (release not read)29 Jan 2026 · 8-K Item 2.02 · Routine · rule score 20
Management change (filing not read)12 Jan 2026 · 8-K Item 5.02 · Routine · rule score 20

Topics are read from the text of the 10-K, 10-Q or the exhibit attached to an 8-K, each linked to the passage it came from. 8-K events are labelled by fixed rules from the item codes and the filing text — the same rules for every company and every year. The Full Picture merges these with earnings calls and news.